Masimo (MASI) 10-Q 1 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 29, 2014
Document And Entity Information [Abstract]	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	29-Mar-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1
Trading Symbol	'MASI
Entity Registrant Name	'MASIMO CORP
Entity Central Index Key	'0000937556
Current Fiscal Year End Date	'--01-03
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	56,737,132

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$117,529	$95,466
Accounts receivable, net of allowance for doubtful accounts of $1,868 and $1,833 at March 29, 2014 and December 28, 2013, respectively	74,065	76,759
Royalties receivable	7,500	7,300
Inventories	55,538	56,813
Prepaid expenses	10,437	9,243
Prepaid income taxes	908	3,740
Deferred tax assets	16,718	19,636
Other current assets	3,986	2,841
Total current assets	286,681	271,798
Deferred cost of goods sold	64,401	61,714
Property and equipment, net	25,486	24,866
Intangible assets, net	28,169	28,104
Goodwill	22,847	22,793
Deferred tax assets	22,552	22,565
Other assets	8,517	6,822
Total assets	458,653	438,662
Current liabilities	'	'
Accounts payable	33,685	28,004
Accrued compensation	22,487	29,486
Accrued liabilities	16,448	23,028
Income taxes payable	2,533	2,406
Deferred revenue	21,680	20,755
Current portion of capital lease obligations	102	111
Total current liabilities	96,935	103,790
Deferred revenue	569	566
Capital lease obligations, less current portion	156	225
Other liabilities	7,550	7,680
Total liabilities	105,210	112,261
Commitments and contingencies	'	'
Masimo Corporation stockholders’ equity:	'	'
Preferred stock, $0.001 par value; 5,000 shares authorized; 0 shares issued and outstanding at March 29, 2014 and December 28, 2013	'	0
Common stock, $0.001 par value; 100,000 shares authorized; 56,737 and 56,623 shares outstanding at March 29, 2014 and December 28, 2013, respectively	57	57
Treasury stock, 4,156 and 4,156 shares at March 29, 2014 and December 28, 2013, respectively	-83,454	-83,454
Additional paid-in capital	277,702	273,129
Accumulated other comprehensive income	4,014	3,995
Retained earnings	155,374	132,742
Total Masimo Corporation stockholders’ equity	353,693	326,469
Noncontrolling interest	-250	-68
Total equity	353,443	326,401
Total liabilities and equity	$458,653	$438,662

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$1,868	$1,833
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	56,737,000	56,623,000
Treasury stock, shares	4,156,000	4,156,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Revenue:	'	'
Product	$132,232	$128,635
Royalty	7,582	7,307
Total revenue	139,814	135,942
Cost of goods sold	47,513	46,361
Gross profit	92,301	89,581
Operating expenses:	'	'
Selling, general and administrative	56,122	52,273
Research and development	13,996	14,167
Litigation award and defense costs	-8,010	0
Total operating expenses	62,108	66,440
Operating income	30,193	23,141
Non-operating income (expense)	200	-2,326
Income before provision for income taxes	30,393	20,815
Provision for income taxes	7,902	4,413
Net income including noncontrolling interest	22,491	16,402
Net loss attributable to the noncontrolling interest	141	26
Net income attributable to Masimo Corporation stockholders	22,632	16,428
Other comprehensive income, net of tax:	'	'
Foreign currency translation adjustments	19	153
Comprehensive income attributable to Masimo Corporation stockholders	$22,651	$16,581
Net income per share attributable to Masimo Corporation stockholders:	'	'
Basic (in usd per share)	$0.40	$0.29
Diluted (in usd per share)	$0.39	$0.28
Weighted average shares used in per share calculations:	'	'
Basic (in shares)	56,705	57,240
Diluted (in shares)	58,047	58,011

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Cash flows from operating activities:	'	'
Net income including noncontrolling interest	$22,491	$16,402
Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:	'	'
Depreciation and amortization	3,043	2,783
Share-based compensation	2,601	3,413
Loss on disposal of property and equipment	2	78
Provision for doubtful accounts	232	142
Provision for deferred income taxes	2,926	0
Income tax benefit from exercise of stock options granted prior to January 1, 2006	24	12
Excess tax (benefit) deficit from share-based compensation arrangements	-31	164
Changes in operating assets and liabilities:	'	'
(Increase) decrease in accounts receivable	2,469	-72
Increase in royalties receivable	-200	-70
(Increase) decrease in inventories	1,288	-1,109
Increase in deferred cost of goods sold	-2,687	-2,741
Increase in prepaid expenses	-1,186	-425
Decrease in prepaid income taxes	2,832	1,492
(Increase) decrease in other assets	-2,831	1,128
Increase in accounts payable	5,676	3,874
Decrease in accrued compensation	-6,996	-3,405
Increase (decrease) in accrued liabilities	-6,587	341
Increase in income taxes payable	156	1,779
Increase in deferred revenue	929	1,102
Increase (decrease) in other liabilities	-130	213
Net cash provided by operating activities	24,021	25,101
Cash flows from investing activities:	'	'
Purchases of property and equipment	-2,840	-1,839
Increase in intangible assets	-886	-1,107
Net cash used in investing activities	-3,726	-2,946
Cash flows from financing activities:	'	'
Repayments of capital lease obligations	-77	-84
Proceeds from issuance of common stock	1,918	463
Excess tax benefit (deficit) from share-based compensation arrangements	31	-164
Repurchases of common stock	0	-12,431
Repurchases of equity by noncontrolling interest	-42	0
Net cash provided by (used in) financing activities	1,830	-12,216
Effect of foreign currency exchange rates on cash	-62	82
Net increase in cash and cash equivalents	22,063	10,021
Cash and cash equivalents at beginning of period	95,466	71,554
Cash and cash equivalents at end of period	$117,529	$81,575

Description_of_the_Company

Description of the Company	3 Months Ended
	Mar. 29, 2014
Accounting Policies [Abstract]	'
Description of the Company	'
	Description of the Company
	Masimo Corporation (Masimo or the Company) is a global medical technology company that develops, manufactures and markets noninvasive patient monitoring products. The Company’s mission is to improve patient outcomes and reduce cost of care by taking noninvasive monitoring to new sites and applications. The Company invented Masimo Signal Extraction Technology, or Masimo SET®, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. The Company has also developed Masimo rainbow® SET products which monitor multiple blood measurements, including oxygen content, carboxyhemoglobin, methemoglobin and hemoglobin. Additional rainbow® SET measurements that assist clinicians are PVI®, RRa®, SpfO2™, Halo Index™ and In Vivo Adjustment™. The Company develops, manufactures and markets a family of patient monitoring solutions which incorporate a monitor or circuit board and sensors, including proprietary single-patient use, reusable and resposable sensors, and cables. The Company sells to hospitals and the alternate care market through its direct sales force and distributors, and markets its circuit boards containing the Company’s proprietary algorithm and software architecture to original equipment manufacturer (OEM) partners.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 29, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial statements. The condensed consolidated balance sheet as of December 28, 2013 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, filed with the SEC on February 14, 2014. The results for the three months ended March 29, 2014 are not necessarily indicative of the results to be expected for the fiscal year ending January 3, 2015 or for any other interim period or for any future year.
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and the variable interest entity, or VIE, of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. In accordance with GAAP, current authoritative guidance is applied when determining whether an entity is subject to consolidation.
	Fiscal Periods
	The Company follows a 52-53 week fiscal year that ends on the Saturday closest to December 31. A 52 week year includes four quarters of 13 fiscal weeks while a 53 week fiscal year includes three 13 fiscal week quarters and one 14 fiscal week quarter. The last 53 week fiscal year was fiscal year 2008. Fiscal year 2014 is a 53 week fiscal year. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
	Use of Estimates
	The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include: determination of accounts receivable allowances, inventory reserves, warranty reserves, rebate reserves, valuation of the Company’s stock options, goodwill valuation, deferred taxes and any associated valuation allowances, distributor channel inventory, royalty revenues, deferred revenue, uncertain income tax positions, property taxes, litigation costs and related accruals. Actual results could differ from such estimates.
	Reclassifications
	Certain amounts in the condensed consolidated financial statements for prior periods have been reclassified to conform to current period presentation.
	Fair Value Measurements
	Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	●	Level 1—Quoted prices in active markets for identical assets or liabilities.
	●	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect the fair value option under this guidance as to specific assets or liabilities. There were no transfers between Level 1, Level 2 and Level 3 inputs during the three months ended March 29, 2014. The Company carries cash and cash equivalents at cost, which approximates fair value. As of March 29, 2014 and December 28, 2013, the Company did not have any short-term investments.
	The following tables represent the Company’s fair value hierarchy for its financial assets (in thousands):
		Fair Value Measurement as of
		March 29, 2014 using:
		Level 1			Level 2			Level 3		Total
	Assets:
	U.S. Treasuries	$	36,998		$	—		$	—	$	36,998
	Money Market funds	1,792			—			—		1,792
	Total	$	38,790		$	—		$	—	$	38,790
		Fair Value Measurement as of
		December 28, 2013 using:
		Level 1			Level 2			Level 3		Total
	Assets:
	U.S. Treasuries	$	25,997		$	—		$	—	$	25,997
	Money Market funds	1,793			—			—		1,793
	Total	$	27,790		$	—		$	—	$	27,790
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consist of trade receivables recorded upon recognition of revenue for product revenues, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on evaluation of the customer’s financial condition. Collateral is not required. The allowance for doubtful accounts is determined based on historical write-off experience, current customer information and other relevant factors, including specific identification of past due accounts, based on the age of the receivable in excess of the contemplated or contractual due date. Accounts are charged off against the allowance when the Company believes they are uncollectible.
	Intangible Assets
	Costs to renew intangibles are capitalized and amortized over the remaining useful life of the intangible. As of March 29, 2014, the weighted average number of years until the next renewal is one year for patents and six years for trademarks.
	The Company’s policy is to renew its patents and trademarks. The Company continually evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
	Impairment of Goodwill and Intangible assets
	Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested at least annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment for each of its reporting units, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. However, if the Company concludes otherwise, then the Company is required to perform the first step of the two-step impairment test by comparing the fair value of the reporting unit, determined using future projected discounted operating cash flows, with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, goodwill is considered impaired and the loss is measured by performing step two. Under step two, the impairment loss is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. The Company also has the option to bypass the qualitative assessment and proceed directly to performing the first step of the two-step goodwill impairment test. The Company may resume performing the qualitative assessment in any subsequent period. The annual impairment test is performed during the fourth fiscal quarter.
	The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
	No impairment of goodwill, intangible assets or other long-lived assets was recorded during the three months ended March 29, 2014 or March 30, 2013.
	Revenue Recognition
	The Company follows the current authoritative guidance for revenue recognition. Based on these requirements, the Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. The Company enters into agreements to sell pulse oximetry and related products and services as well as multiple deliverable arrangements that include various combinations of products and services. While the majority of the Company’s sales transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation is sometimes required to determine the appropriate accounting including: (a) how the arrangement consideration should be allocated among the deliverables if there are multiple deliverables, (b) when to recognize revenue on the deliverables, and (c) whether undelivered elements are essential to the functionality of the delivered elements. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.
	The authoritative guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (VSOE), (ii) third-party evidence of selling price (TPE), and (iii) best estimate of the selling price (ESP). VSOE of fair value is defined as the price charged when the same element is sold separately. VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. TPE generally does not exist for the majority of the Company’s products. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. In the absence of VSOE and TPE, the Company determines ESP for its products by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization, or GPO, contracts, the Company’s pricing and discount practices and market conditions.
	A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. Most of the Company’s products in a multiple deliverable arrangement qualify as separate units of accounting. In the case of the Company’s monitoring equipment containing embedded Masimo SET® software, the Company has determined that the hardware and software components function together to deliver the equipment's essential functionality and, therefore, represent a single deliverable. Software deliverables, such as rainbow® parameter software, which do not function together with hardware components to provide the equipment's essential functionality, are accounted for under software revenue recognition guidance. The revenue for these multiple-element arrangements is allocated to the software deliverables and the non-software deliverables based on the relative selling prices of all of the deliverables in the arrangement using the hierarchy in the revenue recognition accounting guidance for arrangements with multiple deliverables.
	Sales under long-term sensor purchase contracts are generally structured such that the Company agrees to provide at no up-front charge certain monitoring equipment, software, installation, training and ongoing warranty support in exchange for the hospital’s agreement to purchase sensors over the term of the agreement, which generally ranges from three to six years. The sensors are essential to the functionality of the monitoring equipment and, therefore, represent a substantive performance obligation. The Company does not recognize any revenue when the monitoring and related equipment and software are delivered to the hospitals and installation and training are complete. The Company recognizes revenue for these delivered elements, on a pro-rata basis, as the sensors are delivered under the long-term purchase commitment. The cost of the monitoring equipment initially placed at the hospitals is deferred and amortized to cost of goods sold over the life of the underlying long-term sensor purchase contract.
	The Company’s distributors primarily purchase sensor products which they then resell to hospitals that are typically fulfilling their purchase obligations to the Company under the end-user hospitals’ long-term sensor purchase commitments. Upon shipment to the distributor, revenue is deferred until the distributor ships the product to the Company’s customers based on an estimate of the inventory held by each distributor at the end of the accounting period. During the quarter ended March 29, 2014, the Company recorded a true-up to its deferred revenue estimate of approximately $2.6 million as a result of new information related to inventory on-hand at one distributor.
	The Company also provides certain end-user hospitals with the ability to purchase sensors under rebate programs. Under these programs, the end-user hospitals may earn rebates based on their purchasing activity. The Company estimates and provides allowances for these programs at the time of sale as a reduction to revenue.
	The Company also earns revenue from the sale of integrated circuit boards that use the Company’s software technology to OEMs as well as license fees for allowing certain OEMs the right to use the Company’s technology in their products. The license fee is recognized upon shipment of the OEM’s product to its customers, as represented to the Company by the OEM.
	In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue and accounts receivable. The Company estimates returns based on several factors, including contractual limitations and past returns history.
	The Company also records royalty revenue under a patent infringement settlement agreement with Covidien Ltd. (Covidien) based on the estimated U.S. sales of Covidien’s infringing products multiplied by the current royalty rate of 7.75%. This estimated revenue is adjusted prospectively when the Company receives the Covidien royalty report, approximately 60 days after the end of each quarter.
	Product Warranty
	The Company provides a warranty against defects in material and workmanship for a period ranging from six months to one year, depending on the product type. In the case of long-term sales agreements, the Company typically warrants the products for the term of the agreement, which generally ranges from three to six years. In traditional sales activities, including direct and OEM sales, the Company establishes an accrual for the estimated costs of warranty at the time of revenue recognition. Estimated warranty expenses are recorded as an accrued liability, with a corresponding provision to cost of sales. In long-term sales agreements, revenue related to extended warranty is recognized over the life of the contract, while the product warranty costs related to the long-term sales agreements are expensed as incurred.
	Changes in the product warranty accrual were as follows (in thousands):
		Three Months Ended
		March 29,			March 30,
		2014			2013
	Warranty accrual, beginning of period	$	1,161		$	838
	Provision for warranty costs	467			777
	Warranty expenditures	(480		)	(600		)
	Warranty accrual, end of period	$	1,148		$	1,015
	Comprehensive Income
	Authoritative accounting guidance establishes requirements for reporting and disclosure of comprehensive income and its components. Comprehensive income includes foreign currency translation adjustments and related tax benefits, which have been excluded from net income including noncontrolling interest, and reflected in Masimo Corporation stockholders’ equity.
The change in accumulated other comprehensive income is as follows (in thousands):
	Three Months Ended
	March 29, 2014
Accumulated other comprehensive income, beginning of period	$	3,995
Foreign currency translation adjustments	19
Accumulated other comprehensive income, end of period	$	4,014
Net Income Per Share
Basic net income per share attributable to Masimo Corporation for the three months ended March 29, 2014 and March 30, 2013 is computed by dividing net income attributable to Masimo Corporation stockholders by the weighted average number of shares outstanding during each period. The diluted net income per share attributable to Masimo Corporation stockholders for the three months ended March 29, 2014 and March 30, 2013 is computed by dividing the net income attributable to Masimo Corporation stockholders by the weighted average number of shares and potential shares outstanding during each period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options. For the three months ended March 29, 2014 and March 30, 2013, weighted options to purchase 2.8 million and 6.7 million shares of common stock, respectively, were outstanding, but were not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the periods presented. Based on authoritative accounting guidance, the Company adjusted its net income including noncontrolling interest by the amount of net loss attributable to the noncontrolling interest for the three months ended March 29, 2014 and March 30, 2013, to determine its net income attributable to its stockholders. A reconciliation of basic and diluted net income per share attributable to Masimo Corporation stockholders is as follows (in thousands, except per share amounts):
	Three Months Ended
	March 29,			March 30,
	2014			2013
Net income attributable to Masimo Corporation stockholders:
Net income including noncontrolling interest	$	22,491		$	16,402
Net loss attributable to the noncontrolling interest	141			26
Net income attributable to Masimo Corporation stockholders	$	22,632		$	16,428
Basic net income per share attributable to Masimo Corporation stockholders:
Net income attributable to Masimo Corporation stockholders	$	22,632		$	16,428
Weighted average shares outstanding - basic	56,705			57,240
Basic net income per share attributable to Masimo Corporation stockholders	$	0.4		$	0.29
Diluted net income per share attributable to Masimo Corporation stockholders:
Weighted average shares outstanding	56,705			57,240
Diluted share equivalent: stock options	1,342			771
Weighted average shares outstanding - diluted	58,047			58,011
Diluted net income per share attributable to Masimo Corporation stockholders	$	0.39		$	0.28
Seasonality
The healthcare business in the United States and overseas is typically subject to quarterly fluctuations in hospital and other alternative care admissions. Over the past three years, the Company’s third fiscal quarter revenues have experienced a sequential decline from its second fiscal quarter revenues. The Company believes this is due primarily to the summer vacation season in which people throughout the world tend to shift their elective procedures out of the summer holiday season. Another factor affecting quarterly revenues is the traditional “flu season” that often increases hospital and acute care facility admissions during the Company’s first and/or fourth fiscal quarters. Because the Company's non-sales variable operating expenses often do not fluctuate in the same manner as its quarterly product sales, this may cause fluctuations in the Company’s quarterly operating income that are disproportionate to fluctuations in its quarterly revenue.
Recently Adopted Accounting Pronouncements
In July 2013, the FASB issued Accounting Standards Update No. 2013-11, or ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This update required companies to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless certain conditions exist. The Company adopted this update in fiscal year 2013 and such adoption did not have a material impact on the consolidated financial statements.
In July 2012, the FASB issued Accounting Standards Update No. 2012-2, or ASU 2012-2, Intangibles - Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, to allow entities to use a qualitative approach to test indefinite-lived intangible assets for impairment. ASU 2012-2 permits an entity to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is concluded that this is the case, then a quantitative impairment test that exists under current authoritative accounting guidance must be completed. Otherwise, the quantitative impairment test is not required. ASU 2012-2 was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company adopted this update in fiscal year 2013 and such adoption did not have a material impact on the consolidated financial statements.

Variable_Interest_Entity_VIE

Variable Interest Entity (VIE)	3 Months Ended
	Mar. 29, 2014
Variable Interest Entity [Abstract]	'
Variable Interest Entity (VIE)	'
	Variable Interest Entity (VIE)
	The Company follows authoritative guidance for the consolidation of its VIE, which requires an enterprise to determine whether its variable interest gives it a controlling financial interest in a VIE. Determination about whether an enterprise should consolidate a VIE is required to be evaluated continuously as changes to existing relationships or future transactions may result in consolidating or deconsolidating the VIE.
	Cercacor Laboratories, Inc. (Cercacor)
	Cercacor is an independent entity spun off from the Company to its stockholders in 1998. Joe Kiani and Jack Lasersohn, members of the Company’s board of directors, are also members of the board of directors of Cercacor. Joe Kiani, the Company’s Chairman and Chief Executive Officer, is also the Chairman and Chief Executive Officer of Cercacor. The Company is a party to a Cross-Licensing Agreement with Cercacor, which was most recently amended and restated effective January 1, 2007, or the Cross-Licensing Agreement, that governs each party’s rights to certain intellectual property held by the two companies. In addition, the Company entered into a Services Agreement with Cercacor effective January 1, 2007, which governs the general and administrative services the Company provides to Cercacor.
	Under the Cross-Licensing Agreement, the Company granted Cercacor an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® owned by the Company, including all improvements on this technology, for the monitoring of non-vital signs measurements and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs measurements in any product market in which a product is intended to be used by a patient or pharmacist rather than a professional medical caregiver. The Company refers to this market as the Cercacor Market. The Company also granted Cercacor a non-exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® for the measurement of vital signs in the Cercacor Market.
	The Company exclusively licenses from Cercacor the right to make and distribute products in the professional medical caregiver markets, which the Company refers to as the Masimo Market, that utilize rainbow® technology for certain non-invasive measurements, including carbon monoxide, methemoglobin, fractional arterial oxygen saturation and hemoglobin. The Company also has the option to obtain exclusive licenses to make and distribute products that utilize rainbow® technology for the monitoring of other non-vital signs measurements, including blood glucose, in product markets where the product is intended to be used by a professional medical caregiver. To date, the Company has developed and commercially released devices that measure carbon monoxide, methemoglobin and hemoglobin using licensed rainbow® technology. The Company also markets certain other rainbow technologies, such as rainbow Acoustic Monitoring™, the rights to which are owned by the Company and for which no licensing fee is paid to Cercacor.
	The Company’s license to rainbow® technology for these parameters in these markets is exclusive on the condition that the Company continues to pay Cercacor royalties on its products incorporating rainbow® technology, subject to certain minimum aggregate royalty thresholds, and that the Company uses commercially reasonable efforts to develop or market products incorporating the licensed rainbow® technology. The royalty is up to 10% of the rainbow® royalty base, which includes handhelds, tabletop and multi-parameter devices. Handheld products incorporating rainbow® technology will carry up to a 10% royalty rate. For other products, only the proportional amount attributable for that portion of the Company’s devices used to monitor non-vital signs measurements, rather than for monitoring vital signs measurements, and sensors and accessories for measuring only non-vital signs parameters, will be included in the 10% rainbow® royalty base. Effective January 2009, for multi-parameter devices, the rainbow® royalty base includes the percentage of the revenue based on the number of rainbow® enabled measurements. For hospital contracts where the Company places equipment and enters into a sensor contract, the Company pays a royalty to Cercacor on the total sensor contract revenues based on the ratio of rainbow® enabled devices to total devices.
	The current annual minimum aggregate royalty obligation under the license is $5.0 million. Actual aggregate royalty liabilities to Cercacor under the license were $1.5 million and $1.3 million for the three months ended March 29, 2014 and March 30, 2013, respectively. In connection with a change in control of the Company, as defined in the Cross-Licensing Agreement, the minimum aggregate annual royalties for all licensed rainbow® measurements payable to Cercacor will increase to $15 million per year and up to $2 million per year for other rainbow® measurements.
	In February 2009, in order to accelerate the product development of an improved hemoglobin spot-check measurement device, Pronto-7®, the Company’s board of directors agreed to fund additional engineering expenses of Cercacor. Specifically, these expenses included third-party engineering materials and supplies expense as well as 50% of Cercacor’s total engineering and engineering-related payroll expenses, from April 2009 through June 2010, the original anticipated completion date of this product development effort. Since July 2010, Cercacor has continued to assist the Company with product development efforts and charged the Company accordingly. Beginning in 2012, due to a revised estimate of the support required by the Company to complete the various Pronto-7® related projects, the Company’s board of directors approved an increase in the percentage of Cercacor’s total engineering and engineering-related payroll expenses funded by the Company from 50% to 60%. During the three months ended March 29, 2014, and until both parties agree to end these services, Cercacor assisted and will continue to assist the Company with the continuing development efforts related to the new handheld noninvasive multi-parameter spot-check hemoglobin testing device. During the three months ended March 29, 2014 and March 30, 2013, the expenses for these additional services, materials and supplies totaled $0.9 million and $1.1 million, respectively.
	Pursuant to authoritative accounting guidance, Cercacor is consolidated within the Company’s financial statements for all periods presented. The Company is required to consolidate Cercacor since the Company is currently deemed to be the primary beneficiary of Cercacor’s activities. This determination is based primarily on the Company’s obligation to absorb Cercacor’s expected losses, as well as the Company's ability to direct the activities that most significantly impact Cercacor’s economic performance. Accordingly, all intercompany royalties, option and license fees and other charges between the Company and Cercacor as well as all intercompany payables and receivables have been eliminated in the consolidation. Also, all direct engineering expenses that have been incurred by the Company and charged to Cercacor, or that have been incurred by Cercacor and charged to the Company, have not been eliminated and are included as research and development expense in the Company’s condensed consolidated statements of comprehensive income. Upon consolidation, $6.9 million and $7.0 million of deferred revenue related to technology licensed to the Company as of March 29, 2014 and December 28, 2013, respectively, were eliminated. In addition, a net receivable of $1.3 million and $2.0 million due from the Company as of March 29, 2014 and December 28, 2013, respectively, were eliminated.
	Assets of Cercacor can only be used to settle obligations of Cercacor and creditors of Cercacor have no recourse to the general credit of the Company. The condensed consolidated balance sheets include a noncontrolling interest in Cercacor of $(0.2) million and ($0.1) million as of March 29, 2014 and December 28, 2013, respectively, which represents the value of common stock, additional paid in capital and retained earnings of Cercacor, which are not available to the Company. In addition, the condensed consolidated balance sheets include, net of intercompany eliminations, total assets of $6.9 million and $7.0 million as of March 29, 2014 and December 28, 2013, respectively, related to Cercacor. Cercacor’s total assets as of March 29, 2014 included $4.8 million for intangible assets and $1.8 million for property and equipment. Its total assets as of December 28, 2013 included $4.7 million for intangible assets and $1.9 million for property and equipment. The Company's condensed consolidated balance sheets include total liabilities, net of intercompany eliminations, of $1.8 million and $2.3 million as of March 29, 2014 and December 28, 2013, respectively, related to Cercacor.
	For the foreseeable future, the Company anticipates that it will continue to consolidate Cercacor pursuant to the current authoritative accounting guidance; however, in the event that Cercacor is no longer considered a VIE or in the event that the Company is no longer the primary beneficiary of Cercacor, the Company may discontinue consolidating the entity.
	The changes in noncontrolling interest for Cercacor are as follows (in thousands):
		Three Months Ended
		March 29, 2014
	Noncontrolling interest, beginning of period	$	(68	)
	Increase in additional paid-in capital of noncontrolling interest	(41		)
	Net loss attributable to noncontrolling interest	(141		)
	Noncontrolling interest, end of period	$	(250	)

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 29, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. As of March 29, 2014, the Company’s cash balance was $78.7 million, which was comprised of checking accounts. Additionally, the Company had cash equivalents of $38.8 million, consisting of $37.0 million of U.S. Treasury bills and $1.8 million of money market funds. As of December 28, 2013, the Company’s cash balance was $67.7 million, comprised of checking accounts. Additionally, the Company had cash equivalents of $27.8 million, consisting of $26.0 million of U.S. Treasury bills and $1.8 million of money market funds.

Royalties_Receivable

Royalties Receivable	3 Months Ended
	Mar. 29, 2014
Royalties Receivable [Abstract]	'
Royalties Receivable	'
	Royalties Receivable
	The royalty receivable of $7.5 million as of March 29, 2014 represents the Company’s estimated amount due for the three months ended March 29, 2014. Pursuant to the settlement agreement, as amended, with Nellcor Puritan Bennett, Inc. (currently Covidien Ltd., or Covidien), the royalties are paid to the Company based on a percentage of sales of Covidien U.S. based pulse oximetry products. The Company recognizes royalty revenue based on the royalty rate per the settlement agreement multiplied by its estimate of Covidien’s sales for each quarter. Any adjustments to the quarterly estimate are recorded prospectively in the following quarter, when the Company receives the Covidien royalty report and payment, which is generally 60 days after the end of each of Covidien’s fiscal quarters.

Inventories

Inventories	3 Months Ended
	Mar. 29, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined using a standard cost method, which approximates FIFO (first-in, first-out) and includes material, labor and overhead. Inventory valuation allowances are recorded for materials that have become obsolete or are no longer used in current production and for inventory that has a market value less than the carrying value in inventory. Inventories consist of the following (in thousands):
		March 29,		December 28,
		2014		2013
	Raw materials	$	27,533	$	26,758
	Work in-process	6,189		6,310
	Finished goods	21,816		23,745
	Total	$	55,538	$	56,813

Intangible_Assets_Intangible_A

Intangible Assets Intangible Assets	3 Months Ended
	Mar. 29, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	Intangible Assets
	Intangible assets, net consist of the following (in thousands):
		March 29,			December 28,
		2014			2013
	Cost
	Patents	$	19,536		$	18,750
	Customer relationships	7,669			7,669
	Acquired technology	5,580			5,580
	Trademarks	3,366			3,338
	Capitalized software development costs	1,611			1,612
	Other	991			969
	Total cost	$	38,753		37,918
	Accumulated amortization
	Patents	(5,931		)	(5,679		)
	Customer relationships	(1,278		)	(1,086		)
	Acquired technology	(973		)	(834		)
	Trademarks	(705		)	(653		)
	Capitalized software development costs	(1,315		)	(1,270		)
	Other	(382		)	(292		)
	Total accumulated amortization	(10,584		)	(9,814		)
	Net carrying amount	$	28,169		$	28,104
	Total amortization expense for the three months ended March 29, 2014 and March 30, 2013 was $0.8 million and $0.7 million, respectively.
	Estimated amortization expense for future fiscal years is as follows (in thousands):
	Fiscal year	Amount
	2014 (balance of year)	$	3,033
	2015	2,820
	2016	2,561
	2017	2,491
	2018	2,333
	Thereafter	14,931
	Total	$	28,169

Stock_Repurchase_Program

Stock Repurchase Program	3 Months Ended
	Mar. 29, 2014
Equity [Abstract]	'
Stock Repurchase Program	'
	Stock Repurchase Program
	In February 2013, the Company’s board of directors authorized the repurchase of up to 6.0 million shares of the Company’s common stock under a new stock repurchase program. The stock repurchase program may be carried out at the discretion of a committee comprised of the Company’s Chief Executive Officer and Chief Financial Officer through open market purchases, one or more Rule 10b5-1trading plans, block trades and in privately negotiated transactions. During the three months ended March 29, 2014, no shares were repurchased under the new repurchase program. During the three months ended March 30, 2013, 0.8 million shares were repurchased, at an average price of $19.77 per share, for a total repurchase price of $15.4 million.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 29, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation
	On August 7, 2007, in connection with the Company’s initial public offering, the 2007 Stock Incentive Plan, or the 2007 Plan, became effective. Under the 2007 Plan, 3.0 million shares of common stock were initially reserved for future issuance, plus shares available under the prior year equity incentive plans. The options generally vest annually over five years using the straight-line method, unless otherwise provided, and expire ten years from the date of grant. Options granted under the 2007 Plan and the prior year equity incentive plans that for any reason expire, are forfeited, are canceled or become unexercisable under any of the Company's stock incentive plans are automatically added to the share reserve of the 2007 Plan. Pursuant to the “evergreen” provision contained in the 2007 Plan, approximately 1.7 million additional shares of common stock were added to the share reserve of the 2007 Plan on each of January 4, 2009, January 3, 2010, January 1, 2012, December 30, 2012 and December 29, 2013, which represented 3% of the Company’s total shares outstanding as of each of January 3, 2009, January 2, 2010, December 31, 2011, December 29, 2012 and December 28, 2013. No shares were added to the share reserve for the year ended January 1, 2011. Subject to applicable laws, the Company may terminate the 2007 Plan at any time. If not terminated sooner, the 2007 Plan will automatically terminate on August 7, 2017.
	The number and weighted average exercise price of options issued and outstanding under all stock option plans are as follows (in thousands, except for exercise prices):
		Three Months Ended
		March 29, 2014
		Shares			Average
					Exercise Price
	Options outstanding, beginning of period	8,911			$	22.76
	Granted	824			$	28.14
	Canceled	(65	)		$	24.42
	Exercised	(114	)		$	16.63
	Options outstanding, end of period	9,556			$	23.28
	Options exercisable, end of period	5,598			$	23.01
	Options available for grant, end of period	6,472
	The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s share-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
		Three Months Ended
		March 29,		March 30,
		2014		2013
	Risk-free interest rate	1.53% to 1.6%		0.9% to 1.0%
	Expected term	5.1 years		5.5 years
	Estimated volatility	32.5% to 32.8%		37.3% to 39.6%
	Expected dividends	0%		0%
	Weighted-average fair value of options granted	$8.89		$7.34
	The total share-based compensation expense for the three months ended March 29, 2014 and March 30, 2013 was $2.6 million and $3.4 million, respectively. The aggregate intrinsic value of options outstanding, with an exercise price less than the closing price of the Company’s common stock, as of March 29, 2014 was $44.1 million. The aggregate intrinsic value of options exercisable, with an exercise price less than the closing price of the Company’s common stock, as of March 29, 2014 was $29.9 million. The aggregate intrinsic value of options exercised during the three months ended March 29, 2014 was $1.5 million. The aggregate intrinsic value is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The unrecognized share-based compensation as of March 29, 2014 was $29.2 million related to unvested options granted after January 1, 2006. The weighted average remaining contractual term of options outstanding, with an exercise price less than the closing price of the Company’s common stock, as of March 29, 2014 was 6.2 years. The weighted average remaining contractual term of options exercisable, with an exercise price less than the closing price of the Company’s common stock, as of March 29, 2014 was 4.3 years.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	The Company leases its facilities in North America, Europe and Asia under operating lease agreements expiring at various dates through December 2020. Certain facilities leases contain predetermined price escalations and in some cases renewal options. The Company recognizes the lease costs using a straight line method based on total lease payments. The Company also received certain leasehold improvement incentives totaling $0.7 million for its headquarters facilities in the U.S. These leasehold improvement incentives have been recorded as deferred rent and are being amortized as a reduction to rent expense on a straight-line basis over the life of the lease. As of both March 29, 2014 and March 30, 2013, rent expense accrued in excess of the amount paid aggregated $0.7 million and is classified in other liabilities in the accompanying condensed consolidated balance sheets. In addition, the Company leases automobiles in Europe that are classified as operating leases and expire at various dates through June 2015. The majority of these leases are non-cancelable. The Company also has outstanding capital leases for office equipment and computer equipment, all of which are non-cancelable.
	Future minimum lease payments under operating and capital leases for each of the following fiscal years ending on or about December 31 are (in thousands) (including interest):
		As of March 29, 2014
		Operating		Capital		Total
		Leases		Leases
	2014 (balance of year)	$	6,874	$	37	$	6,911
	2015	7,272		87		7,359
	2016	3,777		80		3,857
	2017	1,698		75		1,773
	2018	1,516		—		1,516
	Thereafter	2,174		—		2,174
	Total	$	23,311	$	279	$	23,590
	Rental expense related to operating leases was $1.6 million and $1.3 million for the three months ended March 29, 2014 and March 30, 2013, respectively. The Company leases office equipment and computer equipment, which have interest rates ranging from 4.3% to 12.0% per year and mature on various dates from July 2014 through October 2017.
	Employee Retirement Savings Plan
	In 1996, the Company adopted the Masimo Retirement Savings Plan, or the Plan, which is a 401(k) plan covering the Company’s full-time U.S. employees who meet certain eligibility requirements. In general, the Company matches an employee’s contribution up to 3% of the employee’s compensation, subject to a maximum amount. The Company may also contribute to the Plan on a discretionary basis. The Company contributed $0.6 million and $0.4 million to the Plan for the three months ended March 29, 2014 and March 30, 2013, respectively.
	Employment and Severance Agreements
	As of March 29, 2014, the Company had an employment agreement with one of its key employees that provides for an aggregate annual base salary with annual increases at the discretion of the Compensation Committee of the board of directors. The employment agreement provides for an annual bonus based on the Company’s attainment of certain objectives and goals. The agreement has an initial term of three years, with automatic daily renewal, unless either the Company or the executive notifies the other party of non-renewal of the agreement. Also, under this employment agreement, the key employee may be entitled to receive certain salary, equity, tax, medical and life insurance benefits if he is terminated by the Company, if he terminates his employment for good reason under certain circumstances or if there is a change in control of the Company.
	As of March 29, 2014, the Company had severance plan participation agreements with six of its executive officers. The participation agreements, or Agreements, are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan, or Severance Plan, which became effective on July 19, 2007 and which was amended effective December 31, 2008. Under each of the Agreements, each executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. The executive officers are also required to give the Company six months advance notice of their resignation under certain circumstances.
	Purchase Commitments
	Pursuant to contractual obligations with vendors, the Company had $60.7 million of purchase commitments as of March 29, 2014, which are expected to be purchased within one year. These purchase commitments were made for certain inventory items to secure better pricing and to ensure the Company will have raw materials when necessary.
	Concentrations of Risk
	The Company is exposed to credit loss for the amount of cash deposits with financial institutions in excess of federally insured limits. The Company invests its excess cash deposits in U.S. Treasury bills and money market accounts with major financial institutions. As of March 29, 2014, the Company had $78.7 million of bank balances, of which $2.6 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations. As of March 29, 2014, the Company had $1.8 million in money market funds that are not guaranteed by the U.S. Federal government.
	While the Company and its contract manufacturers rely on sole source suppliers for certain components, steps have been taken to minimize the impact of a shortage or stoppage of shipments, such as maintaining a safety stock of inventory and designing products that may be easily modified to use a different component. However, there can be no assurance that a shortage or stoppage of shipments of the materials or components that the Company purchases will not result in a delay in production or adversely affect the Company’s business.
	The Company’s ability to sell its products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended March 29, 2014 and March 30, 2013, revenue from the sale of the Company’s products to U.S. hospitals that are members of GPOs amounted to $75.2 million and $73.5 million, respectively.
	As of March 29, 2014, two different just-in-time distributors each represented 7% and 8% of the accounts receivable balance. As of December 28, 2013, two different just-in-time distributors each represented 8% and 9% of the accounts receivable balance.
	For the three months ended March 29, 2014, the Company had sales through two just-in-time distributors, which each represented 15% and 9% of the total revenue. For the three months ended March 30, 2013, the Company had sales through two just-in-time distributors, which each represented 14% and 11% of the total revenue. For both periods, the just-in-time distributors took and fulfilled orders from the Company’s direct customers, many of whom have signed long-term sensor agreements with the Company.
	For the three months ended March 29, 2014 and March 30, 2013, the Company recorded $7.6 million and $7.3 million, respectively, in royalty revenues from Covidien pursuant to the original settlement agreement and amendments. In exchange for these royalty payments, the Company has provided Covidien the ability to ship its patent infringing product with a covenant not to sue Covidien as long as Covidien abides by the terms of the agreement. The current royalty rate is 7.75% and the amended agreement can be terminated by Covidien upon sixty days written notice.
	Litigation
	On February 3, 2009, the Company filed a patent infringement suit against Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH (collectively, Philips) related to Philips’ FAST pulse oximetry technology and certain of Philips' patient monitors. The suit was brought in the U.S. District Court for the District of Delaware. Two patents originally asserted in this suit, related to the Company’s Measure-Through Motion technology, were successfully enforced in the Company’s previous suit against Nellcor. On June 15, 2009, Philips answered the Company’s complaint and Philips Electronics North America Corporation filed antitrust and patent infringement counterclaims against the Company as well as counterclaims seeking declaratory judgments of invalidity on the patents asserted by the Company against Philips. On July 9, 2009, the Company filed its answer denying Philips’ counterclaims and asserting various defenses. The Company also asserted counterclaims against Philips for fraud, intentional interference with prospective economic advantage and for declaratory judgments of noninfringement and invalidity with respect to the patents asserted by Philips against the Company. Philips later added a claim for infringement of one additional patent. Subsequently, the Court bifurcated Philips’ antitrust claims and its patent misuse defense, as well as stayed the discovery phase on those claims pending trial in the patent case. On October 4, 2010, the Court limited the number of patents to be construed to four for the Company and three for Philips. Further, on October 6, 2010, the Court denied Philips’ motion to bifurcate and stay damages in the patent case. On January 17, 2012, the District Court Judge issued a claim construction order. In 2012, the parties completed expert reports and discovery on some of the patents. In addition, in 2012, the Company asserted additional patents, and the Court ordered that these patents and some of the originally asserted patents be tried in a second phase. In 2013, the Magistrate Judge issued reports and recommendations relating to various summary judgment motions filed by the parties. On December 2, 2013, the Court heard oral argument on the parties’ objections to the Magistrate Judge’s reports and recommendations. On March 31, 2014, the District Court Judge ruled on the objections. On April 14, 2014, the parties filed motions for reconsideration of certain rulings. The parties have requested a trial date in September 2014. The Company believes that it has good and substantial defenses to the antitrust and patent infringement claims asserted by Philips. There is no guarantee that the Company will prevail in this suit or receive any damages or other relief if it does prevail.
	On December 21, 2012, the Company filed suit against Mindray DS USA, Inc. and Shenzhen Mindray Bio-Medical Electronics Co, Ltd. (Shenzhen Mindray) in the U.S. District Court for the Central District of California. The complaint alleges patent infringement, breach of contract and other claims. Mindray DS USA, Inc. was dismissed from this case based on venue. On June 3, 2013, Shenzhen Mindray answered the Company’s complaint and filed antitrust and related counterclaims against the Company, as well as counterclaims seeking declaratory judgments of invalidity and non-infringement on the patents asserted by the Company against Shenzhen Mindray. On June 24, 2013, the Company filed its answer denying Shenzhen Mindray’s counterclaims and asserting various defenses. On July 17, 2013, the Court granted Shenzhen Mindray’s motion to dismiss the patent claims without prejudice to allow the Company to amend the complaint to provide additional detail supporting Shenzhen Mindray’s direct and indirect infringement of the Company’s patents. On the same day, the Court denied Shenzhen Mindray’s motion to dismiss the Company’s non-patent claims. On August 5, 2013, the Company filed a first amended complaint. On August 21, 2013, Shenzhen Mindray answered the Company’s complaint and reasserted the counterclaims it asserted on June 3, 2013, as well as two additional counterclaims alleging patent infringement. On September 16, 2013, the Company filed its answer denying Shenzhen Mindray’s counterclaims and asserting various defenses. On October 31, 2013, the Court issued a scheduling order setting a trial date of November 4, 2014. On December 10, 2013, Shenzhen Mindray filed a second amended answer and counterclaims, including a new counterclaim for tortious interference. On January 2, 2014, the Company filed a motion for judgment on the pleadings as to Shenzhen Mindray’s antitrust counterclaims and inequitable conduct counterclaims and defenses. The Court granted judgment on the pleadings with leave to amend. On March 27, 2014, Shenzhen Mindray filed a third amended answer and counterclaims. On April 10, 2014, Shenzhen Mindray filed a fourth amended answer and counterclaims, which motion is pending before the Court. The Company believes that it has good and substantial defenses to the antitrust, patent infringement and other counterclaims asserted by Shenzhen Mindray. There is no guarantee that the Company will prevail in this suit or receive any damages or other relief if it does prevail.
	On December 10, 2013, the Company filed suit against Mindray DS USA, Inc., Shenzhen Mindray and Mindray Medical International Ltd. in the Superior Court of New Jersey. The complaint alleges breach of contract and related claims. On January 17, 2014, Mindray DS USA filed a notice of removal removing the case to the U.S. District Court for the District of New Jersey. On January 24, 2014, Mindray DS USA, Inc. filed a motion seeking to dismiss or stay the action in view of the Company’s action against Shenzhen Mindray in the Central District of California. That motion is pending before the Court and no order from the Court has issued. On April 15, 2014, Mindray Medical International filed a motion to dismiss based on lack of personal jurisdiction, challenging service of process, and alleging that the Company failed to state a claim. That motion is also pending before the Court. There is no guarantee that the Company will prevail in this suit or receive any damages or other relief if it does prevail.
	In September 2012, a shareholder derivative lawsuit was filed in the U.S. District Court for the District of Delaware by Joseph Ausikaitis naming the Company’s directors and certain executive officers as defendants and the Company as the nominal defendant. The lawsuit alleges claims of breach of fiduciary duty and unjust enrichment in connection with the grant or receipt of stock options under the Company’s 2007 Stock Incentive Plan and related policies. The lawsuit seeks unspecified money damages on the Company’s behalf from the officer and director defendants, various forms of equitable and/or injunctive relief, attorneys’ and other professional fees and costs and various other forms of relief. In November 2012, the defendants filed a motion to dismiss the action, which was denied by the court in July 2013. Although the outcome in this case cannot be determined, the Company does not expect it to have a material financial impact on its results of operations.
	In April 2011, the Company was informed by the United States Attorney’s Office for the Central District of California, Civil Division, that a qui tam complaint had been filed against the Company in the U.S. District Court for the Central District of California by three of the Company's former physician office sales representatives. The qui tam complaint alleged, among other things, that the Company's noninvasive hemoglobin products failed to meet their accuracy specifications, and that the Company misled the FDA and customers regarding the accuracy of the products. In November 2011, the United States declined to intervene in the case, and in October 2013, the District Court granted summary judgment in the Company’s favor. The former sales representatives are appealing the District Court’s decision.
	In September 2011, two of the same former sales representatives also filed employment-related claims against the Company in arbitration also stemming from their allegations regarding the Company’s noninvasive hemoglobin products. On January 16, 2014, the Company was notified that the arbitrator awarded the plaintiffs approximately $5.4 million in damages, which the Company accrued in fiscal 2013. In addition, the Company’s insurance carrier notified the Company that it believed certain defense costs related to the arbitration may no longer be reimbursable in view of the arbitration decision. As a result, the Company accrued a liability of $2.6 million in fiscal 2013 for the costs estimated to have been paid by the insurance carrier. The Company challenged the arbitration award in the U.S. District Court for the Central District of California, and on April 3, 2014, the District Court vacated the award. Accordingly, the Company reversed the $8.0 million charge in the quarter ended March 29, 2014. The former sales representatives are appealing the District Court’s decision. The Company is unable to predict the final outcome of the qui tam and employment matters. A reversal of the District Court’s decision in either matter could have a material adverse effect on the Company’s financial condition or results of operations in the future.
	On January 2, 2014, a putative class action complaint was filed against the Company in the U.S. District Court for the Central District of California by Physicians Healthsource, Inc. The complaint alleges that the Company sent unsolicited facsimile advertisements in violation of the Junk Fax Protection Act of 2005 and related regulations. The complaint seeks $500 for each alleged violation, treble damages if the court finds the alleged violations to be knowing, plus interest, costs and injunctive relief. On April 14, 2014, the Company filed a motion to stay the case pending a decision on a related petition filed by the Company with the Federal Communications Commission (FCC). The motion to stay is pending. The Company believes it has good and substantial defenses to the claims, but there is no guarantee that the Company will prevail.
	On January 31, 2014, an amended putative class action complaint was filed against the Company in the U.S. District Court for the Northern District of Alabama by and on behalf of two participants in the Surfactant, Positive Pressure, and Oxygenation Randomized Trial at the University of Alabama. On April 21, 2014, a further amended complaint was filed adding a third participant. The complaint alleges product liability and negligence claims in connection with pulse oximeters the Company modified and provided at the request of study investigators for use in the trial. A previous version of the complaint also alleged a wrongful death claim, which the court dismissed on January 22, 2014. The amended complaint seeks unspecified damages, costs, interest, attorney fees, and injunctive and other relief. The Company believes it has good and substantial defenses to the remaining claims, but there is no guarantee that the Company will prevail.
	From time to time, the Company may be involved in other litigation relating to claims arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Segment_Information_and_Enterp

Segment Information and Enterprise Reporting	3 Months Ended
	Mar. 29, 2014
Segment Reporting [Abstract]	'
Segment Information and Enterprise Reporting	'
	Segment Information and Enterprise Reporting
	The Company’s chief decision maker, the Chief Executive Officer, reviews financial information presented on a consolidated basis, accompanied by disaggregated information about revenues by geographic region, for purposes of making operating decisions and assessing financial performance. Accordingly, the Company considers itself to be in a single reporting segment, specifically noninvasive patient monitoring solutions and related products. The Company does not assess the performance of its geographic regions on other measures of income or expense, such as depreciation and amortization, operating income or net income including noncontrolling interest. In addition, the Company’s assets are primarily located in the U.S. The Company does not produce reports for, or measure the performance of, its geographic regions on any asset-based metrics. Therefore, geographic information is presented only for revenues.
	The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):
		Three Months Ended
		March 29, 2014				March 30, 2013
	Geographic Area by Destination
	North and South America	$	92,652	70.1	%	$	98,722	76.7	%
	Europe, Middle East and Africa	27,012		20.4		18,836		14.6
	Asia and Australia	12,568		9.5		11,077		8.6
	Total product revenue	$	132,232	100	%	$	128,635	100	%
	United States	$	88,047			$	94,269

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 29, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company has provided for income taxes in fiscal 2014 interim periods based on the estimated effective income tax rate for the complete fiscal year. The income tax provision is computed on the estimated pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not.
	Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant management judgment. The Company’s judgment regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances. A valuation allowance has been previously recorded against all of the deferred tax assets of Cercacor. On a quarterly basis, Cercacor's management reassesses the need for these valuation allowances based on operating results and its assessment of the likelihood of future taxable income and developments in the relevant tax jurisdictions. Cercacor continues to maintain a full valuation allowance as of March 29, 2014 against its net deferred tax assets.
	As of March 29, 2014, the liability for income taxes associated with uncertain tax positions was approximately $6.7 million. If fully recognized, approximately $5.7 million (net of federal benefit on state taxes) would impact the Company's effective tax rate. The remaining balance relates to timing differences. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
	The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters for each year through 2009. All material state, local and foreign income tax matters have been concluded for each year through 2006.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 29, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Event
	On April 23, 2014, the Company entered into a five-year revolving credit facility with JPMorgan Chase Bank, National Association (the Bank), that matures on April 23, 2019 (the Credit Facility). The Credit Facility provides for up to an aggregate of $125 million in borrowings in multiple currencies. Borrowings under the Credit Facility will be deemed, at the Company’s election, either: (i) an ABR Loan, which bears interest at the Alternate Base Rate (as defined below) plus a spread of 0.225% to 1.250% based on the Company’s Total Leverage Ratio (as defined in the Credit Facility), or (ii) a Eurodollar Loan, which bears interest at the Adjusted LIBO Rate (as defined below) plus a spread of 1.125% to 2.250% based on the Company's Total Leverage Ratio. The Company may also request swingline loans from time to time, subject to certain conditions (Swingline Loans) that bear interest similar to an ABR Loan.
	The Alternate Base Rate is determined by taking the greatest of (i) the prime rate, (ii) the federal funds effective rate plus 0.50% and (iii) the one-month Adjusted LIBO Rate plus 1.00%. The Adjusted LIBO Rate is equal to LIBOR for the applicable interest period multiplied by the statutory reserve rate for such period.
	The Company is obligated under the Credit Facility to pay a fee ranging from to 0.225% to 0.300% per annum, based upon the Company’s Total Leverage Ratio, with respect to any unused portion of the Credit Facility. This fee and interest on any ABR Loan are due and payable quarterly in arrears. Interest on any Eurodollar Loan is due and payable at the end of the applicable interest period (or at each three month interval in the case of loans with interest periods greater than three months). Interest on any Swingline Loan is due and payable on the date that the Swingline Loan is required to be repaid. The Company may prepay the loans and terminate the commitments in whole at any time, without premium or penalty, subject to reimbursement of certain costs in the case of Eurodollar Loans.
	Pursuant to the terms of the Credit Facility, the Company is subject to certain customary financial and negative covenants. The Company’s obligations under the Credit Facility are secured by substantially all of the Company’s personal property, including all equity interests in domestic subsidiaries and first-tier foreign subsidiaries. Proceeds from the Credit Facility will be used for general corporate, capital investment and working capital purposes.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 29, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial statements. The condensed consolidated balance sheet as of December 28, 2013 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, filed with the SEC on February 14, 2014. The results for the three months ended March 29, 2014 are not necessarily indicative of the results to be expected for the fiscal year ending January 3, 2015 or for any other interim period or for any future year.
Principles of Consolidation	'
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and the variable interest entity, or VIE, of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. In accordance with GAAP, current authoritative guidance is applied when determining whether an entity is subject to consolidation.
Fiscal Periods	'
	Fiscal Periods
	The Company follows a 52-53 week fiscal year that ends on the Saturday closest to December 31. A 52 week year includes four quarters of 13 fiscal weeks while a 53 week fiscal year includes three 13 fiscal week quarters and one 14 fiscal week quarter. The last 53 week fiscal year was fiscal year 2008. Fiscal year 2014 is a 53 week fiscal year. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Use of Estimates	'
	Use of Estimates
	The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include: determination of accounts receivable allowances, inventory reserves, warranty reserves, rebate reserves, valuation of the Company’s stock options, goodwill valuation, deferred taxes and any associated valuation allowances, distributor channel inventory, royalty revenues, deferred revenue, uncertain income tax positions, property taxes, litigation costs and related accruals. Actual results could differ from such estimates.
Fair Value Measurements	'
	Fair Value Measurements
	Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	●	Level 1—Quoted prices in active markets for identical assets or liabilities.
	●	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect the fair value option under this guidance as to specific assets or liabilities. There were no transfers between Level 1, Level 2 and Level 3 inputs during the three months ended March 29, 2014. The Company carries cash and cash equivalents at cost, which approximates fair value. As of March 29, 2014 and December 28, 2013, the Company did not have any short-term investments.
Accounts Receivable and Allowance for Doubtful Accounts	'
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable consist of trade receivables recorded upon recognition of revenue for product revenues, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on evaluation of the customer’s financial condition. Collateral is not required. The allowance for doubtful accounts is determined based on historical write-off experience, current customer information and other relevant factors, including specific identification of past due accounts, based on the age of the receivable in excess of the contemplated or contractual due date. Accounts are charged off against the allowance when the Company believes they are uncollectible.
Intangible Assets	'
	Intangible Assets
	Costs to renew intangibles are capitalized and amortized over the remaining useful life of the intangible. As of March 29, 2014, the weighted average number of years until the next renewal is one year for patents and six years for trademarks.
	The Company’s policy is to renew its patents and trademarks. The Company continually evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Impairment of Goodwill and Intangible assets	'
	Impairment of Goodwill and Intangible assets
	Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested at least annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment for each of its reporting units, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. However, if the Company concludes otherwise, then the Company is required to perform the first step of the two-step impairment test by comparing the fair value of the reporting unit, determined using future projected discounted operating cash flows, with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, goodwill is considered impaired and the loss is measured by performing step two. Under step two, the impairment loss is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. The Company also has the option to bypass the qualitative assessment and proceed directly to performing the first step of the two-step goodwill impairment test. The Company may resume performing the qualitative assessment in any subsequent period. The annual impairment test is performed during the fourth fiscal quarter.
	The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Revenue Recognition	'
	Revenue Recognition
	The Company follows the current authoritative guidance for revenue recognition. Based on these requirements, the Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured. The Company enters into agreements to sell pulse oximetry and related products and services as well as multiple deliverable arrangements that include various combinations of products and services. While the majority of the Company’s sales transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation is sometimes required to determine the appropriate accounting including: (a) how the arrangement consideration should be allocated among the deliverables if there are multiple deliverables, (b) when to recognize revenue on the deliverables, and (c) whether undelivered elements are essential to the functionality of the delivered elements. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.
	The authoritative guidance provides a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (VSOE), (ii) third-party evidence of selling price (TPE), and (iii) best estimate of the selling price (ESP). VSOE of fair value is defined as the price charged when the same element is sold separately. VSOE generally exists only when the deliverable is sold separately and is the price actually charged for that deliverable. TPE generally does not exist for the majority of the Company’s products. The objective of ESP is to determine the price at which the Company would transact a sale if the product was sold on a stand-alone basis. In the absence of VSOE and TPE, the Company determines ESP for its products by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization, or GPO, contracts, the Company’s pricing and discount practices and market conditions.
	A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. Most of the Company’s products in a multiple deliverable arrangement qualify as separate units of accounting. In the case of the Company’s monitoring equipment containing embedded Masimo SET® software, the Company has determined that the hardware and software components function together to deliver the equipment's essential functionality and, therefore, represent a single deliverable. Software deliverables, such as rainbow® parameter software, which do not function together with hardware components to provide the equipment's essential functionality, are accounted for under software revenue recognition guidance. The revenue for these multiple-element arrangements is allocated to the software deliverables and the non-software deliverables based on the relative selling prices of all of the deliverables in the arrangement using the hierarchy in the revenue recognition accounting guidance for arrangements with multiple deliverables.
	Sales under long-term sensor purchase contracts are generally structured such that the Company agrees to provide at no up-front charge certain monitoring equipment, software, installation, training and ongoing warranty support in exchange for the hospital’s agreement to purchase sensors over the term of the agreement, which generally ranges from three to six years. The sensors are essential to the functionality of the monitoring equipment and, therefore, represent a substantive performance obligation. The Company does not recognize any revenue when the monitoring and related equipment and software are delivered to the hospitals and installation and training are complete. The Company recognizes revenue for these delivered elements, on a pro-rata basis, as the sensors are delivered under the long-term purchase commitment. The cost of the monitoring equipment initially placed at the hospitals is deferred and amortized to cost of goods sold over the life of the underlying long-term sensor purchase contract.
	The Company’s distributors primarily purchase sensor products which they then resell to hospitals that are typically fulfilling their purchase obligations to the Company under the end-user hospitals’ long-term sensor purchase commitments. Upon shipment to the distributor, revenue is deferred until the distributor ships the product to the Company’s customers based on an estimate of the inventory held by each distributor at the end of the accounting period. During the quarter ended March 29, 2014, the Company recorded a true-up to its deferred revenue estimate of approximately $2.6 million as a result of new information related to inventory on-hand at one distributor.
	The Company also provides certain end-user hospitals with the ability to purchase sensors under rebate programs. Under these programs, the end-user hospitals may earn rebates based on their purchasing activity. The Company estimates and provides allowances for these programs at the time of sale as a reduction to revenue.
	The Company also earns revenue from the sale of integrated circuit boards that use the Company’s software technology to OEMs as well as license fees for allowing certain OEMs the right to use the Company’s technology in their products. The license fee is recognized upon shipment of the OEM’s product to its customers, as represented to the Company by the OEM.
	In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue and accounts receivable. The Company estimates returns based on several factors, including contractual limitations and past returns history.
	The Company also records royalty revenue under a patent infringement settlement agreement with Covidien Ltd. (Covidien) based on the estimated U.S. sales of Covidien’s infringing products multiplied by the current royalty rate of 7.75%. This estimated revenue is adjusted prospectively when the Company receives the Covidien royalty report, approximately 60 days after the end of each quarter.
Product Warranty	'
	Product Warranty
	The Company provides a warranty against defects in material and workmanship for a period ranging from six months to one year, depending on the product type. In the case of long-term sales agreements, the Company typically warrants the products for the term of the agreement, which generally ranges from three to six years. In traditional sales activities, including direct and OEM sales, the Company establishes an accrual for the estimated costs of warranty at the time of revenue recognition. Estimated warranty expenses are recorded as an accrued liability, with a corresponding provision to cost of sales. In long-term sales agreements, revenue related to extended warranty is recognized over the life of the contract, while the product warranty costs related to the long-term sales agreements are expensed as incurred.
Comprehensive Income	'
	Comprehensive Income
	Authoritative accounting guidance establishes requirements for reporting and disclosure of comprehensive income and its components. Comprehensive income includes foreign currency translation adjustments and related tax benefits, which have been excluded from net income including noncontrolling interest, and reflected in Masimo Corporation stockholders’ equity.
Net Income Per Share	'
	Net Income Per Share
	Basic net income per share attributable to Masimo Corporation for the three months ended March 29, 2014 and March 30, 2013 is computed by dividing net income attributable to Masimo Corporation stockholders by the weighted average number of shares outstanding during each period. The diluted net income per share attributable to Masimo Corporation stockholders for the three months ended March 29, 2014 and March 30, 2013 is computed by dividing the net income attributable to Masimo Corporation stockholders by the weighted average number of shares and potential shares outstanding during each period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options. For the three months ended March 29, 2014 and March 30, 2013, weighted options to purchase 2.8 million and 6.7 million shares of common stock, respectively, were outstanding, but were not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the periods presented. Based on authoritative accounting guidance, the Company adjusted its net income including noncontrolling interest by the amount of net loss attributable to the noncontrolling interest for the three months ended March 29, 2014 and March 30, 2013, to determine its net income attributable to its stockholders.
New Accounting Pronouncement	'
	Recently Adopted Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standards Update No. 2013-11, or ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This update required companies to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, unless certain conditions exist. The Company adopted this update in fiscal year 2013 and such adoption did not have a material impact on the consolidated financial statements.
	In July 2012, the FASB issued Accounting Standards Update No. 2012-2, or ASU 2012-2, Intangibles - Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment, to allow entities to use a qualitative approach to test indefinite-lived intangible assets for impairment. ASU 2012-2 permits an entity to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is concluded that this is the case, then a quantitative impairment test that exists under current authoritative accounting guidance must be completed. Otherwise, the quantitative impairment test is not required. ASU 2012-2 was effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company adopted this update in fiscal year 2013 and such adoption did not have a material impact on the consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 29, 2014
Accounting Policies [Abstract]	'
Fair Value Hierarchy for Financial Assets	'
	The following tables represent the Company’s fair value hierarchy for its financial assets (in thousands):
		Fair Value Measurement as of
		March 29, 2014 using:
		Level 1			Level 2			Level 3		Total
	Assets:
	U.S. Treasuries	$	36,998		$	—		$	—	$	36,998
	Money Market funds	1,792			—			—		1,792
	Total	$	38,790		$	—		$	—	$	38,790
		Fair Value Measurement as of
		December 28, 2013 using:
		Level 1			Level 2			Level 3		Total
	Assets:
	U.S. Treasuries	$	25,997		$	—		$	—	$	25,997
	Money Market funds	1,793			—			—		1,793
	Total	$	27,790		$	—		$	—	$	27,790
Changes in Product Warranty Accrual	'
	Changes in the product warranty accrual were as follows (in thousands):
		Three Months Ended
		March 29,			March 30,
		2014			2013
	Warranty accrual, beginning of period	$	1,161		$	838
	Provision for warranty costs	467			777
	Warranty expenditures	(480		)	(600		)
	Warranty accrual, end of period	$	1,148		$	1,015
Schedule of Change in Accumulated Other Comprehensive Income	'
	The change in accumulated other comprehensive income is as follows (in thousands):
		Three Months Ended
		March 29, 2014
	Accumulated other comprehensive income, beginning of period	$	3,995
	Foreign currency translation adjustments	19
	Accumulated other comprehensive income, end of period	$	4,014
Reconciliation of Basic and Diluted Net Income Per Share	'
	A reconciliation of basic and diluted net income per share attributable to Masimo Corporation stockholders is as follows (in thousands, except per share amounts):
		Three Months Ended
		March 29,			March 30,
		2014			2013
	Net income attributable to Masimo Corporation stockholders:
	Net income including noncontrolling interest	$	22,491		$	16,402
	Net loss attributable to the noncontrolling interest	141			26
	Net income attributable to Masimo Corporation stockholders	$	22,632		$	16,428
	Basic net income per share attributable to Masimo Corporation stockholders:
	Net income attributable to Masimo Corporation stockholders	$	22,632		$	16,428
	Weighted average shares outstanding - basic	56,705			57,240
	Basic net income per share attributable to Masimo Corporation stockholders	$	0.4		$	0.29
	Diluted net income per share attributable to Masimo Corporation stockholders:
	Weighted average shares outstanding	56,705			57,240
	Diluted share equivalent: stock options	1,342			771
	Weighted average shares outstanding - diluted	58,047			58,011
	Diluted net income per share attributable to Masimo Corporation stockholders	$	0.39		$	0.28

Variable_Interest_Entity_VIE_T

Variable Interest Entity (VIE) (Tables)	3 Months Ended
	Mar. 29, 2014
Variable Interest Entity [Abstract]	'
Changes in Noncontrolling Interest for Cercacor	'
	The changes in noncontrolling interest for Cercacor are as follows (in thousands):
		Three Months Ended
		March 29, 2014
	Noncontrolling interest, beginning of period	$	(68	)
	Increase in additional paid-in capital of noncontrolling interest	(41		)
	Net loss attributable to noncontrolling interest	(141		)
	Noncontrolling interest, end of period	$	(250	)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 29, 2014
Inventory Disclosure [Abstract]	'
Components of Inventory	'
	Inventories consist of the following (in thousands):
		March 29,		December 28,
		2014		2013
	Raw materials	$	27,533	$	26,758
	Work in-process	6,189		6,310
	Finished goods	21,816		23,745
	Total	$	55,538	$	56,813

Intangible_Assets_Intangible_A1

Intangible Assets Intangible Assets (Tables)	3 Months Ended
	Mar. 29, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets	'
	Intangible assets, net consist of the following (in thousands):
		March 29,			December 28,
		2014			2013
	Cost
	Patents	$	19,536		$	18,750
	Customer relationships	7,669			7,669
	Acquired technology	5,580			5,580
	Trademarks	3,366			3,338
	Capitalized software development costs	1,611			1,612
	Other	991			969
	Total cost	$	38,753		37,918
	Accumulated amortization
	Patents	(5,931		)	(5,679		)
	Customer relationships	(1,278		)	(1,086		)
	Acquired technology	(973		)	(834		)
	Trademarks	(705		)	(653		)
	Capitalized software development costs	(1,315		)	(1,270		)
	Other	(382		)	(292		)
	Total accumulated amortization	(10,584		)	(9,814		)
	Net carrying amount	$	28,169		$	28,104
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	'
	Estimated amortization expense for future fiscal years is as follows (in thousands):
	Fiscal year	Amount
	2014 (balance of year)	$	3,033
	2015	2,820
	2016	2,561
	2017	2,491
	2018	2,333
	Thereafter	14,931
	Total	$	28,169

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 29, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans	'
	The number and weighted average exercise price of options issued and outstanding under all stock option plans are as follows (in thousands, except for exercise prices):
		Three Months Ended
		March 29, 2014
		Shares			Average
					Exercise Price
	Options outstanding, beginning of period	8,911			$	22.76
	Granted	824			$	28.14
	Canceled	(65	)		$	24.42
	Exercised	(114	)		$	16.63
	Options outstanding, end of period	9,556			$	23.28
	Options exercisable, end of period	5,598			$	23.01
	Options available for grant, end of period	6,472
Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant	'
	The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
		Three Months Ended
		March 29,		March 30,
		2014		2013
	Risk-free interest rate	1.53% to 1.6%		0.9% to 1.0%
	Expected term	5.1 years		5.5 years
	Estimated volatility	32.5% to 32.8%		37.3% to 39.6%
	Expected dividends	0%		0%
	Weighted-average fair value of options granted	$8.89		$7.34

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments Under Operating and Capital Leases	'
	Future minimum lease payments under operating and capital leases for each of the following fiscal years ending on or about December 31 are (in thousands) (including interest):
		As of March 29, 2014
		Operating		Capital		Total
		Leases		Leases
	2014 (balance of year)	$	6,874	$	37	$	6,911
	2015	7,272		87		7,359
	2016	3,777		80		3,857
	2017	1,698		75		1,773
	2018	1,516		—		1,516
	Thereafter	2,174		—		2,174
	Total	$	23,311	$	279	$	23,590

Segment_Information_and_Enterp1

Segment Information and Enterprise Reporting (Tables)	3 Months Ended
	Mar. 29, 2014
Segment Reporting [Abstract]	'
Analysis of Product Revenues Based upon Geographic Area Shipped	'
	The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):
		Three Months Ended
		March 29, 2014				March 30, 2013
	Geographic Area by Destination
	North and South America	$	92,652	70.1	%	$	98,722	76.7	%
	Europe, Middle East and Africa	27,012		20.4		18,836		14.6
	Asia and Australia	12,568		9.5		11,077		8.6
	Total product revenue	$	132,232	100	%	$	128,635	100	%
	United States	$	88,047			$	94,269

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Fair Value Hierarchy for Financial Assets (Detail) (Recurring, USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Fair value hierarchy for financial assets	'	'
Total	$38,790	$27,790
U.S. Treasuries	'	'
Fair value hierarchy for financial assets	'	'
Total	36,998	25,997
Money Market funds	'	'
Fair value hierarchy for financial assets	'	'
Total	1,792	1,793
Level 1	'	'
Fair value hierarchy for financial assets	'	'
Total	38,790	27,790
Level 1 | U.S. Treasuries	'	'
Fair value hierarchy for financial assets	'	'
Total	36,998	25,997
Level 1 | Money Market funds	'	'
Fair value hierarchy for financial assets	'	'
Total	1,792	1,793
Level 2	'	'
Fair value hierarchy for financial assets	'	'
Total	0	0
Level 2 | U.S. Treasuries	'	'
Fair value hierarchy for financial assets	'	'
Total	0	0
Level 2 | Money Market funds	'	'
Fair value hierarchy for financial assets	'	'
Total	0	0
Level 3	'	'
Fair value hierarchy for financial assets	'	'
Total	0	0
Level 3 | U.S. Treasuries	'	'
Fair value hierarchy for financial assets	'	'
Total	0	0
Level 3 | Money Market funds	'	'
Fair value hierarchy for financial assets	'	'
Total	$0	$0

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
Share data in Millions, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'
Impairment of goodwill, intangible assets and other long-lived assets	$0	$0
True up on deferred revenue	$2,600,000	'
Rate Of royalty agreed to be paid	7.75%	'
Number of days royalty revenue is adjusted subsequent to quarter end	'60 days	'
Warranty period, minimum, long-term sales agreement	'3 years	'
Warranty period, maximum, long-term sales agreement	'6 years	'
Options to purchase of shares of common stock	2.8	6.7
Patents	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Weighted average number of years until the next renewal	'1 year	'
Trademarks	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Weighted average number of years until the next renewal	'6 years	'
Minimum	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Product life estimate	'3 years	'
Warranty period for defects in material and workmanship	'6 months	'
Maximum	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Product life estimate	'6 years	'
Warranty period for defects in material and workmanship	'1 year	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]	'	'
Warranty accrual, beginning of period	$1,161	$838
Provision for warranty costs	467	777
Warranty expenditures	-480	-600
Warranty accrual, end of period	$1,148	$1,015

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Change in Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Accounting Policies [Abstract]	'	'
Accumulated other comprehensive income, beginning of period	$3,995	'
Foreign currency translation adjustments	19	153
Accumulated other comprehensive income, end of period	$4,014	'

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Net income attributable to stockholders of Masimo Corporation:	'	'
Net income including noncontrolling interest	$22,491	$16,402
Net loss attributable to the noncontrolling interest	141	26
Net income attributable to Masimo Corporation stockholders	22,632	16,428
Basic net income per share attributable to Masimo Corporation stockholders:	'	'
Net income attributable to Masimo Corporation stockholders	$22,632	$16,428
Weighted average shares outstanding - basic (in shares)	56,705	57,240
Basic net income per share attributable to Masimo Corporation stockholders (in usd per share)	$0.40	$0.29
Diluted net income per share attributable to Masimo Corporation stockholders:	'	'
Weighted average shares outstanding - basic (in shares)	56,705	57,240
Diluted share equivalent: stock options (in shares)	1,342	771
Weighted average shares outstanding - diluted (in shares)	58,047	58,011
Diluted net income per share attributable to Masimo Corporation stockholders (in usd per share)	$0.39	$0.28

Variable_Interest_Entity_VIE_A

Variable Interest Entity (VIE) - Additional Information (Detail) (USD $)	Mar. 29, 2014	Dec. 28, 2013	Mar. 29, 2014	Mar. 29, 2014	Feb. 28, 2009	Mar. 29, 2014	Mar. 30, 2013	Dec. 28, 2013	Dec. 31, 2011	Mar. 29, 2014
			Licensed rainbow parameters	Handheld Products Incorporating Rainbow Technology	Variable Interest Entity, Primary Beneficiary	Variable Interest Entity, Primary Beneficiary	Variable Interest Entity, Primary Beneficiary	Variable Interest Entity, Primary Beneficiary	Variable Interest Entity, Primary Beneficiary	Minimum
										Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]	'	'	'	'	'	'	'	'	'	'
Percentage of royalty expense	'	'	10.00%	10.00%	'	'	'	'	'	'
Minimum aggregate royalty payments	'	'	'	'	'	$1,500,000	$1,300,000	'	'	$5,000,000
Increase in royalties payable in current year	'	'	'	'	'	15,000,000	'	'	'	'
Increase in the minimum aggregate annual royalties payment	'	'	'	'	'	2,000,000	'	'	'	'
Percentage reimbursed	'	'	'	'	50.00%	60.00%	'	'	50.00%	'
Total expenses for additional services, materials and supplies	'	'	'	'	'	900,000	1,100,000	'	'	'
Deferred revenue related to technology eliminated upon consolidation	'	'	'	'	'	6,900,000	'	7,000,000	'	'
Accounts receivable (payable) eliminated upon consolidation, net	'	'	'	'	'	1,300,000	'	2,000,000	'	'
Noncontrolling interest	-250,000	-68,000	'	'	'	-200,000	'	-100,000	'	'
Total assets, net of intercompany eliminations	'	'	'	'	'	6,900,000	'	7,000,000	'	'
Intangible assets	'	'	'	'	'	4,800,000	'	4,700,000	'	'
Property and equipment	'	'	'	'	'	1,800,000	'	1,900,000	'	'
Total liabilities, net of intercompany eliminations	'	'	'	'	'	$1,800,000	'	$2,300,000	'	'

Variable_Interest_Entity_VIE_C

Variable Interest Entity (VIE) - Changes in Noncontrolling Interest for Cercacor (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Variable Interest Entity [Abstract]	'	'
Noncontrolling interest, beginning of period	($68)	'
Increase in additional paid-in capital of noncontrolling interest	-41	'
Net loss attributable to noncontrolling interest	-141	-26
Noncontrolling interest, end of period	($250)	'

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2014	Dec. 28, 2013
Cash and Cash Equivalents [Abstract]	'	'
Highly liquid investments maximum maturity period	'Three months or less	'
Cash balance	$78.70	$67.70
Cash equivalents	38.8	27.8
US Government Securities, at Carrying Value	37	26
Money market funds	$1.80	$1.80

Royalties_Receivable_Additiona

Royalties Receivable - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2014
Royalties Receivable [Abstract]	'
Royalty receivable	$7.50
Number of days after which royalty report and payment is received	'60 days

Inventories_Components_of_Inve

Inventories - Components of Inventory (Detail) (USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$27,533	$26,758
Work in-process	6,189	6,310
Finished goods	21,816	23,745
Total	$55,538	$56,813

Intangible_Assets_Intangible_A2

Intangible Assets Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) (USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	$38,753	$37,918
Total accumulated amortization	-10,584	-9,814
Net carrying amount	28,169	28,104
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	19,536	18,750
Total accumulated amortization	-5,931	-5,679
Customer relationships	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	7,669	7,669
Total accumulated amortization	-1,278	-1,086
Acquired technology	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	5,580	5,580
Total accumulated amortization	-973	-834
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	3,366	3,338
Total accumulated amortization	-705	-653
Capitalized software development costs	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	1,611	1,612
Total accumulated amortization	-1,315	-1,270
Other	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total cost	991	969
Total accumulated amortization	($382)	($292)

Intangible_Assets_Intangible_A3

Intangible Assets Intangible Assets - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Amortization of Intangible Assets	$0.80	$0.70

Intangible_Assets_Intangible_A4

Intangible Assets Intangible Assets - Future Amortization Expense (Details) (USD $)	Mar. 29, 2014	Dec. 28, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
2014	$3,033	'
2015	2,820	'
2016	2,561	'
2017	2,491	'
2018	2,333	'
Thereafter	14,931	'
Net carrying amount	$28,169	$28,104

Stock_Repurchase_Program_Addit

Stock Repurchase Program - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013	Feb. 28, 2013
Equity [Abstract]	'	'	'
Number of common shares authorized to be repurchased under new stock repurchase program	'	'	6,000,000
Stock repurchase program, number of shares repurchased	0	800,000	'
Stock repurchase program, average price per share	'	$19.77	'
Stock repurchase program, total value	'	$15.40	'

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

In Millions, except Share data, unless otherwise specified

Mar. 29, 2014

Mar. 30, 2013

Dec. 28, 2013

Dec. 29, 2012

Dec. 31, 2011

Jan. 01, 2011

Jan. 02, 2010

Feb. 24, 2014

Feb. 15, 2013

Feb. 17, 2012

Aug. 04, 2010

Mar. 04, 2009

Mar. 29, 2014

Aug. 07, 2007

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

2007 Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of options to purchase shares

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

Vesting period of options

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

Expiration period of options

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Common stock shares added to share reserve

'

'

'

'

'

'

'

1,700,000

1,700,000

1,700,000

1,700,000

1,700,000

'

'

Percentage of Company's total shares outstanding

'

'

3.00%

3.00%

3.00%

3.00%

3.00%

'

'

'

'

'

'

'

Share-based compensation expense

$2.60

$3.40

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding

44.1

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercisable

29.9

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercised

1.5

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized share-based compensation related to unvested options granted

$29.20

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized share-based compensation related to unvested options granted, term

'6 years 2 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining contractual term of options exercisable, years

'4 years 3 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Number

Share-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Options outstanding, beginning of period	8,911
Granted	824
Canceled	-65
Exercised	-114
Options outstanding, end of period	9,556
Options exercisable, end of period	5,598
Options available for grant, end of period	6,472
Average Exercise Price	'
Options outstanding, beginning of period	$22.76
Granted	$28.14
Canceled	$24.42
Exercised	$16.63
Options outstanding, end of period	$23.28
Options exercisable, end of period	$23.01

ShareBased_Compensation_Range_

Share-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) (USD $)	3 Months Ended
	Mar. 29, 2014	Mar. 30, 2013
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant	'	'
Risk-free interest rate, minimum	1.53%	0.90%
Risk-free interest rate, maximum	1.60%	1.00%
Expected term	'5 years 1 month 6 days	'5 years 6 months
Estimated volatility, minimum	32.50%	37.30%
Estimated volatility, maximum	32.80%	39.60%
Expected dividends	0.00%	0.00%
Weighted-average fair value of options granted	$8.89	$7.34

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Sep. 30, 2011

Mar. 29, 2014

Mar. 30, 2013

Jan. 31, 2014

Dec. 28, 2013

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Dec. 28, 2013

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 30, 2013

Mar. 29, 2014

Mar. 29, 2014

Dec. 28, 2013

Mar. 29, 2014

Dec. 28, 2013

Feb. 03, 2009

Oct. 04, 2010

Jul. 09, 2009

Aug. 21, 2013

Jan. 16, 2014

Dec. 28, 2013

Jan. 03, 2014

sales_representatives

Agreement

participant

Customer concentration risk

Customer concentration risk

Accounts Receivable

Accounts Receivable

Sales

Sales

Minimum

Maximum

Automobiles

Just in time distributor one

Just in time distributor one

Just in time distributor two

Just in time distributor two

Masimo vs. Nellcor

Masimo vs. Philips

Masimo vs. Philips

Masimo vs. Mindray DS USA, Inc. and Shenzhen Mindray Bio-Medical Electronics

Masimo vs Former Physician Office Sales Representatives

Masimo vs Former Physician Office Sales Representatives

Masimo vs. Physicians Healthsource, Inc.

distributor

distributor

distributor

distributor

patent

construction

patent

claim

Contingencies And Commitments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Leasehold improvement incentives received

'

$700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued rent expense

'

700,000

800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating lease expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Jun-15

'

'

'

'

'

'

'

'

'

'

'

Rental expense related to operating leases

'

1,600,000

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rates on capital lease

'

'

'

'

'

'

'

'

'

'

'

4.30%

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

Company contribution percentage based on employee contribution of up to 3% of employee's compensation

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's contribution to employee retirement savings plan

'

600,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial term of agreement

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Severance plan participation agreements

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation

'

60,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank balances

'

78,700,000

'

'

67,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bank balance covered by Federal Deposit Insurance Corporation limit

'

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Money market funds

'

1,800,000

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of company's products to customers

'

'

'

'

'

75,200,000

73,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, just-in-time distributors

'

'

'

'

'

'

'

2

2

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of accounts receivable balance from two just-in-time distributor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

8.00%

8.00%

9.00%

'

'

'

'

'

'

'

Percentage of revenue one customer

'

15.00%

14.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenue two customer

'

9.00%

11.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty

'

7,582,000

7,307,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Rate Percentage

'

7.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain contingency, patents found infringed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Number of patents allegedly infringed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

Loss contingency, patents allegedly infringed, patent court limitation on defendent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

Loss contingency, patents allegedly infringed, patent court limitation on plaintiff

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

Loss contingency, new claims filed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

Number of former sales representatives

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Litigation settlement amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,400,000

'

'

Litigation settlement expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,600,000

'

Increase (decrease) in loss contingency accrual

'

-8,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss contingency, damages sought

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$500

Number of participants in the surfactant, positive pressure, and oxygenation randomized trial

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments Under Operating and Capital Leases (Detail) (USD $)	Mar. 29, 2014
In Thousands, unless otherwise specified
Operating Leases	'
2014 (balance of year)	$6,874
2015	7,272
2016	3,777
2017	1,698
2018	1,516
Thereafter	2,174
Total	23,311
Capital Leases	'
2014 (balance of year)	37
2015	87
2016	80
2017	75
2018	0
Thereafter	0
Total	279
Total	'
2014 (balance of year)	6,911
2015	7,359
2016	3,857
2017	1,773
2018	1,516
Thereafter	2,174
Total	$23,590

Segment_Information_and_Enterp2

Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2014	Mar. 30, 2013
Analysis of Product Revenues Based upon the Geographic Area Shipped	'	'
Total product revenue	$132,232	$128,635
Total product revenue, in percentage	100.00%	100.00%
North and South America | Reportable Geographical Components	'	'
Analysis of Product Revenues Based upon the Geographic Area Shipped	'	'
Total product revenue	92,652	98,722
Total product revenue, in percentage	70.10%	76.70%
Europe, Middle East and Africa | Reportable Geographical Components	'	'
Analysis of Product Revenues Based upon the Geographic Area Shipped	'	'
Total product revenue	27,012	18,836
Total product revenue, in percentage	20.40%	14.60%
Asia and Australia | Reportable Geographical Components	'	'
Analysis of Product Revenues Based upon the Geographic Area Shipped	'	'
Total product revenue	12,568	11,077
Total product revenue, in percentage	9.50%	8.60%
United States | Reportable Geographical Components	'	'
Analysis of Product Revenues Based upon the Geographic Area Shipped	'	'
Total product revenue	$88,047	$94,269

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Mar. 29, 2014
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Gross unrecognized tax benefit	$6.70
Unrecognized tax benefit that would affect effective tax rate	$5.70

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (Subsequent Event, Revolving Credit Facility, USD $)	0 Months Ended
	Apr. 23, 2014
Line of Credit Facility [Line Items]	'
Term of revolving credit facility	'5 years
Maximum borrowing capacity	$125,000,000
Minimum	'
Line of Credit Facility [Line Items]	'
Facility fee percentage on unused amount of line of credit	0.23%
Maximum	'
Line of Credit Facility [Line Items]	'
Facility fee percentage on unused amount of line of credit	0.30%
Base Rate | Minimum	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	0.23%
Base Rate | Maximum	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	1.25%
Adjusted LIBOR | Minimum	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	1.13%
Adjusted LIBOR | Maximum	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	2.25%
Federal Funds	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	0.50%
Credit Agreement | One Month LIBOR	'
Line of Credit Facility [Line Items]	'
Basis spread on variable rate	1.00%